The seed round was backed by angel investors alongside Founders Factory and IFG.VC.
"The search for the ideal home is no longer reliant on the preconceived notion of location being everything. People’s priorities have shifted to lifestyle needs and the market is not yet accounting for this. Thanks to our unique technology we are flipping the traditional property search process on its head: by considering our users’ budget, commute, and location requirements, we help our users uncover the homes and neighbourhoods that are going to be the right fit for their needs. We are focussed on using the benefits of AI technology and data to push our matchmaking capabilities even further, to help uncover the hidden data that renters and buyers care a lot about."
The seed round was backed by Cambridge Angels, Angel Academe, Syndicate Room, and Founders Factory, with Alex Hirsch leading the investment.
"The idea for Scale XP came when – particularly once the pandemic hit – we identified a huge demand among the small business community for an easy-to-use tool that can support them on their growth journey. We wanted to give them an easier way to oversee their business performance, holistically, so that they can thrive. I’m delighted by the huge interest and support from the VC community and female founder networks like Angel Academe to help us realise this mission. It’s fantastic to have Alex on the Advisory Board to help us scale the business quickly."
The seed round was led by Hoxton Ventures with backing from dRx Capital and Founders Factory.
"Our sole focus at Peptone is to embrace experimental failure and, in fact, acknowledge it as an absolutely vital stage in the process of getting the design of protein-based medicines right. Great science is always born out of failure. The reality is that drug discovery in Big Pharma sees only a small fraction of protein based drugs pass the preclinical stages due to their complexity. Pharma, just like any industry, is subject to the ‘power law’. A small number of innovative drugs generate disproportional benefits to patients and outsized capital returns. We are working on shifting this failure-to-success ratio in a meticulously predictable and repeatable way using the best computational methods and scalable data science. Only last week one of our clients produced a monoclonal antibody for which our platform suggested seven radical mutations. The said therapeutic protein got vastly improved. The probability of a human researcher being able to engineer this type of change is equal to 1/1,280,000,000. In layman terms you are four times more likely to win the Powerball lottery than to spontaneously find the solution our platform has identified in less than ten days. The business of protein therapeutics is a huge industry and as we grow and further develop our supercomputing capacity we can help make significant progress in the time to market for much sought-after protein-based treatments."
The seed round was led by Pink Salt Ventures and Founders Factory to help scale production and expand the team.
"My doctor didn’t identify the early symptoms of perimenopause. I didn’t fit the profile. I was ‘too young’ and still having a regular cycle. I was advised to take ‘time out’ to address exhaustion and upweight my vitamin intake. My experience isn’t unusual. Menopause simply isn’t well enough understood or researched. It is presented as an end-of-life category when it should be a midlife empowerment category."
